Clinical trial

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

NCT06611813

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-06-11

PhasePHASE2

Study timeline

Study start (actual)2024-06-11Date precision: day

Registry last updated2025-08-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HR+/HER2- Breast Cancerunresolved

Interventions

Neoadjuvant Chemotherapy in Combination with ToripalimabDRUG

HR+ HER2 breast cancerDRUG

Sponsors & collaborators

First Affiliated Hospital of Zhejiang Universitylead sponsor

Mapped research locations

HangzhouChina2 ShanghaiChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06611813 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.